Workflow
龙津药业(002750) - 2019 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was ¥57,100,397.27, a decrease of 32.09% year-on-year[7] - Net profit attributable to shareholders was ¥465,799.05, down 87.07% compared to the same period last year[7] - Basic earnings per share decreased by 86.67% to ¥0.0012[7] - Revenue fell by 25.22% to ¥188,250,723.97, impacted by national healthcare cost control policies and prescription restrictions[13] - The company reported a net profit of CNY 202,375,772.56 for the period, compared to CNY 199,879,965.61 in the previous period, marking a slight increase[31] - Total operating revenue for the current period is $57.1 million, down from $84.1 million in the previous period, representing a decrease of approximately 32.1%[33] - Net profit for the current period is $1.23 million, a significant decline from $3.62 million in the previous period, indicating a decrease of approximately 66.1%[37] - The total profit for the current period is $1.83 million, down from $3.79 million in the previous period, representing a decrease of about 51.7%[37] - The company reported a total profit for the period was ¥3,814,392.01, down 76.4% from ¥16,116,117.43 in the previous period[41] Cash Flow - The net cash flow from operating activities increased by 201.56% to ¥13,333,754.46[7] - Cash flow from operating activities was ¥222,629,811.28, compared to ¥300,563,302.86 in the previous period[48] - The net cash flow from operating activities for Q3 2019 was ¥8,370,279.18, a decrease from ¥8,664,507.39 in Q3 2018, reflecting a decline of approximately 3.4%[49] - Total cash inflow from operating activities was ¥236,716,323.85, compared to ¥306,319,007.08 in the previous year, indicating a decrease of about 22.7%[49] - The net cash flow from financing activities was ¥19,250,900.00, compared to -¥12,015,000.00 in the previous year, marking a significant improvement[50] Assets and Liabilities - Total assets at the end of the reporting period reached ¥790,492,163.35, an increase of 0.37% compared to the previous year[7] - The company's total liabilities were CNY 104,286,523.13, down from CNY 131,616,795.52, indicating a decrease of approximately 20.7%[25] - Current liabilities decreased to CNY 73,320,527.11 from CNY 99,434,952.60, representing a reduction of about 26.3%[25] - Non-current assets totaled CNY 338,758,101.97, up from CNY 314,980,193.45, reflecting a growth of approximately 7.0%[26] - Owner's equity increased to CNY 686,205,640.22 from CNY 655,932,947.33, showing a growth of about 4.6%[26] Shareholder Information - The total number of shareholders at the end of the reporting period was 39,670[9] - The largest shareholder, Kunming Qunxing Investment Co., Ltd., held 42.38% of shares, totaling 169,724,647 shares[9] - The company did not engage in any repurchase transactions during the reporting period[10] Research and Development - R&D expenses decreased by 38.32% to ¥13,993,041.17, as capitalized development costs were reported[13] - The company has ongoing development expenditures of CNY 11,789,673.91, significantly higher than CNY 4,753,149.27 from the previous year, indicating a focus on new product development[29] Financial Ratios - The weighted average return on net assets was 0.07%, a decrease of 0.49% year-on-year[7] - Financial income rose significantly by 1221.51% to -¥9,197,703.67, due to increased interest income[14] - The company experienced a significant increase in financial expenses, with a net financial cost of -¥9,197,703.67 compared to -¥696,001.97 in the previous period[39] Investment Activities - The net cash flow from investing activities was -¥42,758,351.10, compared to -¥35,236,231.51 in the same period last year, showing a worsening of about 21.5%[50] - Cash inflow from investment activities was ¥30,431,068.50, significantly lower than ¥976,454,202.69 in Q3 2018, a decrease of approximately 96.9%[50] - Cash outflow from investment activities reached ¥73,189,419.60, down from ¥1,011,690,434.20, indicating a decline of about 92.8%[50]